DHRSX

Across TCGA pan-cancer cohorts, DHRSX Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DHRSX data layer compared with 23 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher DHRSX Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DHRSX expression acts as an unfavorable survival marker.

COAD, SARC, and PRAD are the cancer types where DHRSX Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	0.140	0.783	<.001	18	view →
SARC	DFS	Median	All	0.121	0.611	.041	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	All	0.386	0.786	.002	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DHRSX–COAD (DFS)

Open the COAD breakdown →